MaxCyte Ownership
| MXCT Stock | USD 3.55 0.10 2.90% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
MaxCyte |
MaxCyte Stock Ownership Analysis
About 71.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.34. The entity had not issued any dividends in recent years. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 84 people. To find out more about MaxCyte contact Maher Masoud at 301 944 1700 or learn more at https://www.maxcyte.com.Besides selling stocks to institutional investors, MaxCyte also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different MaxCyte's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align MaxCyte's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
MaxCyte Quarterly Liabilities And Stockholders Equity |
|
MaxCyte Insider Trades History
Only 1.49% of MaxCyte are currently held by insiders. Unlike MaxCyte's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against MaxCyte's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of MaxCyte's insider trades
MaxCyte Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MaxCyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MaxCyte backward and forwards among themselves. MaxCyte's institutional investor refers to the entity that pools money to purchase MaxCyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Portolan Capital Management, Llc | 2024-06-30 | 1.7 M | Swedbank Ab | 2024-09-30 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | Chevy Chase Trust Holdings, Inc. | 2024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Ameriprise Financial Inc | 2024-06-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 860.3 K | Silvercrest Asset Management Group Llc | 2024-06-30 | 708.2 K | Centerbook Partners Lp | 2024-09-30 | 585.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 9.3 M | Cadian Capital Management Lp | 2024-09-30 | 8.2 M |
MaxCyte Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MaxCyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on MaxCyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MaxCyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MaxCyte Outstanding Bonds
MaxCyte issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MaxCyte uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MaxCyte bonds can be classified according to their maturity, which is the date when MaxCyte has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MAY DEPT STORES Corp BondUS577778BH56 | View | |
| MAY DEPT STORES Corp BondUS577778BQ55 | View | |
| MAY DEPT STORES Corp BondUS577778CE17 | View |
MaxCyte Corporate Filings
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 16th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.